The clinically most established serological biomarker, AFP, shows only a limited diagnostic performance for detecting early-stage HCC; however, when combined with age, gender, AFP-L3, and DCP (GALAD model), it shows promising diagnostic utility, in various etiologies of HCC, for early-stage HCC. The gene discussed is ACE; the disease is hepatocellular carcinoma.